Bruker Corporation (BRKR) Earnings

Management highlights

Overall Business Performance • Bruker returned to organic revenue growth in Q2 2026, marking the fourth consecutive quarter with a scientific instruments book-to-bill ratio above 1.0, with 10% YoY organic bookings growth. • Organic bookings grew over 20% in biopharma driven by NMR, X-ray, and mass spectrometry solutions; Deep Tech Semiconductor Tools and Energy Research Technologies both achieved over 50% YoY organic order growth. • US academic/government orders remained weak in Q2, but European and Chinese academic/government bookings grew strongly. • Deep tech tools typically have 9–24 month delivery timelines tied to customer facility readiness, so strong current bookings will primarily benefit revenue starting in Q4 2026, continuing through 2027 and beyond. Organizational Restructuring • Effective July 1, 2026, Bruker implemented a new operating structure with four core groups: Bruker Biosystems, Bruker Nano, BMIT, and BEST, aligning the company with customer market needs. • Bruker Biosystems combines former BioSpin, mass spectrometry, and optics divisions to deliver integrated connected workflows for life science, drug discovery, and advanced materials research, and is expected to drive improved agility and investment prioritization. • BMIT was spun out from the former CALIT group as a standalone group focused on the fast-growing microbiology and infection diagnostics market. The new structure is expected to deliver an additional $20 million in annualized cost reductions in 2027. Cost Savings and Profitability • The company is well on track to hit its target of $140 million in annualized cost savings in 2026, with $30 million in cost savings delivered in Q2 2026 alone. • Q2 2026 non-GAAP gross margin was 52.1% (up 350 bps YoY), non-GAAP operating margin was 14.1% (up 510 bps YoY), and non-GAAP diluted EPS was 49 cents, up 53% YoY, driven by cost savings, tariff refunds, and favorable volume mix. • Geographically, Americas and European organic revenue grew ~10% YoY in Q2, while Asia-Pacific (including China) revenue declined low double digits YoY.

Guidance

• Full year 2026 organic revenue growth guidance is maintained at 1% to 2% YoY, with acquisition contribution unchanged at 1.5%. Reported revenue guidance is updated to $3.54–$3.57 billion (3%–4% reported growth YoY), adjusted for a lower expected FX tailwind of 0.5% (down from 1.5% previously). • Full year 2026 non-GAAP operating margin expansion guidance is maintained at 250–300 bps YoY, and non-GAAP EPS guidance is unchanged at $2.10–$2.15, representing 15%–17% YoY EPS growth. • Approximately $20 million of planned Q3 2026 semiconductor revenue will shift to Q4 2026 due to customer delivery timing requirements, resulting in Q3 2026 organic revenue expected to be roughly flat to slightly up YoY. • Q3 2023 non-GAAP operating margin and EPS are expected to see a slight sequential decrease, due to the revenue shift and the early pull-forward of a 6 cent tariff-related EPS benefit into Q2 from Q3. • Q4 2026 is expected to deliver meaningful sequential and YoY increases in organic revenue, operating margin, and EPS, with total revenue expected to be around $1 billion, driven by higher volume and favorable mix. • Management expects organic growth acceleration in 2027 compared to 2026, but cannot yet quantify the full year growth rate, and targets long-term EBIT operating margin expansion to the low 20% range.

Segment performance

Bruker reported total Q2 2026 revenues of $839 million, up 5.2% year-over-year, with organic growth of 2.8% (3.4% excluding tariff refunds). M&A contributed 1.5% revenue growth, and FX provided a 0.9% tailwind, for constant exchange rate growth of 4.3%. - Bruker Biosystems (BSI): Organic revenue grew 2.3% in Q2 2026; in H1 2026, legacy BioSpin revenue was $393 million (mid-single digits YoY decline), legacy CALIT group revenue was $627 million (mid-single digits YoY increase), with strength in biopharma and security detection, offset by weaker US revenues. - Bruker Nano: H1 2026 revenue was $507 million (low single digits YoY decline), with weakness in academic/government and industrial markets largely offset by strong AI-driven demand for semiconductor metrology tools. Organic order growth for semiconductor metrology exceeded 30% H1 2026, with organic revenue growth over 15% and a 30% EBIT margin. - Bruker Microbiology and Infection Diagnostics (BMIT): H1 2026 molecular diagnostics revenue grew solidly, while microbiology revenue was roughly flat YoY. - Bruker Energy and Supercon Technologies (BEST): Q2 2026 organic revenue grew 8.9% YoY net of intercompany eliminations; H1 2026 revenue grew 6% YoY net of eliminations, with strong growth in superconductors and solid growth in research instruments. H1 2026 high energy research orders grew over 100% YoY, while security detection orders and revenue both grew ~20% YoY.

Risks & headwinds

• The company recorded a $135 million non-cash goodwill impairment charge in Q2 2026 GAAP results related to the automation and spatial biology businesses, which continue to generate operating losses. • Persistent weakness in US academic/government funding and orders continues to negatively impact near-term revenue performance. • Longer lead times for deep tech and semiconductor products delay revenue recognition relative to order growth. • Foreign exchange rate volatility creates headwinds for top-line performance, with a projected FX headwind in Q3 2026 after a lower than expected tailwind in Q2. • Supply chain challenges for electronic components persist, though current impacts are already baked into full year guidance. • Geopolitical risks, trade tariffs, wars, blockades, competitive dynamics, and fluctuating market demand create uncertainty for actual results relative to forward-looking projections.

Analyst Q&A

• Q: How did Bruker account for U.S. tariff refunds, what is the impact to guidance, and can you elaborate on the sustainability and revenue timing of strong 50% semiconductor order growth driven by AI?

  A: Some tariff charges passed to customers are recorded as contra-revenue, and the Q2 2026 tariff benefit added 200 bps to operating margin and 6 cents to EPS. All tariff refunds were already baked into original full year guidance, with only an earlier pull-forward into Q2. Semiconductor demand driven by AI looks very sustainable through 2027, with excellent visibility for at least the next six quarters. Most orders have 3–8 quarter lead times driven by customer fab readiness, so revenue recognition will be delayed, with most hitting starting in Q4 2026 and continuing into 2027 and 2028.

• Q: Q2 organic revenue was lighter than expected even ex-tariffs — is there any unexpected weakness, and how will margin progress through the second half of 2026 after the strong Q2 tariff-driven margin beat?

  A: The only unexpected factors were the 60 bps revenue impact from tariff refunds and a 50 bps lower than expected FX tailwind; the core revenue weakness came from US academic/government revenue, which was down over $15 million YoY due to weak H2 2025 orders. Q3 margins will see a slight sequential decline because of the $20 million semiconductor revenue shift to Q4 and the early pull-through of tariff benefits to Q2. Q4 will see strong margin expansion and EPS growth from higher volume, better mix, and large delivered orders.

• Q: Is the 250–300 bps full year operating margin expansion target still intact, how are input costs and inflation trending, and what is the improvement outlook for academic/government orders?

  A: The full year 2026 operating margin expansion target is unchanged. Cost saving efforts are on track to hit the $140 million annual target, with additional savings from the new organizational structure coming in 2027. Energy and material cost pressure is already baked into guidance, with only modest ongoing electronic component supply chain challenges. US academic/government orders remain weak despite higher NIH outlays, but non-US academic/government orders grew over 10% YoY in Europe and over 20% in China during Q2, with strong portfolio competitiveness driving market share gains outside the US.

• Q: How strong is unanticipated demand for security detection and energy research, and is this growth sustainable into 2027?

  A: Security detection order growth of ~20% was incrementally better than expected, and demand looks very sustainable driven by ongoing global security and defense concerns, with strong differentiated products and good margins. Energy research order growth of over 100% greatly exceeded expectations at the start of the year; this very high growth rate is not sustainable, but the underlying business has strong multi-year visibility from large long-term fusion and high energy physics projects, so solid revenue growth will continue through 2027 and beyond.